Categories Earnings

Antares Pharma: Q4 2017 earnings snapshot

Specialty pharma firm Antares Pharma (ATRS) pared down its losses in the fourth quarter due to reduced R&D expenses. The company reported a loss of $3.7 million or $0.02 per share compared to $4.4 million or $0.03 per share in the prior year period. Sales declined marginally by 1% to $14 million.

On the products front, OTREXUP sales improved 17% to $4.8 million and auto injector devices sales more than doubled to $3.1 million. Development revenues decreased to $2.2 million as products under development is getting ready for market launch. With its partner AMAG Pharmaceuticals’ Makena product getting FDA approval, the company expects its top line to improve in 2018 as AMAG uses Antares’ QuickShot auto injector.

For fiscal 2017, sales improved 4% to $54.5 million, while net loss reduced to $16.7 million compared to $24.2 million, helped by reduced expenses.

Antares earnings

Most Popular

DG Earnings Preview: What to look for when Dollar General reports Q3 results

Discount store chain Dollar General Corporation (NYSE: DG) will be reporting third-quarter results next week. Operating nearly 20,000 stores across the US, it is one of the largest supermarket chains

Dollar Tree (DLTR): A few points to note about the discount retailer’s Q3 performance

Shares of Dollar Tree, Inc. (NASDAQ: DLTR) were up over 1% on Thursday. The stock has dropped 13% year-to-date. The discount retailer delivered third-quarter 2023 earnings results that did not

KR Earnings: Key quarterly highlights from Kroger’s Q3 2023 financial results

The Kroger Co. (NYSE: KR) reported its third quarter 2023 earnings results today. Total company sales were $34 billion compared to $34.2 billion for the same period last year. Identical sales

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top